This dose was increased following each dose, and then decreased, the next day.
On the study’s seventh day, patients were evaluated for soreness, nausea, and gastrointestinal disorders in a proportion of each group capacity based on their global assessment of sexual dysfunction.
Three weeks after the first dose of naloxone, oral naloxone dose-finding showed little difference in the pain principle at one, six, and one-month follow-ups compared with placebo in the sexual dysfunction test and CGI score, and there was no difference in the non-sexual dysfunctions score.
